ALTITUDE clinical science initiative will provide insights to ICD and CRT-D
NATICK, Mass., May 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced a new clinical science initiative, ALTITUDE, which will analyze data(1) from the LATITUDE(R) Patient Management system. The initiative will use the substantial LATITUDE data to seek answers to common questions related to implantable cardiac defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) device therapy. The ALTITUDE initiative will be managed in collaboration with an external physician panel of thought leaders who will assist in identifying relevant clinical issues for examination.
Boston Scientific has enrolled nearly 100,000 patients on the LATITUDE Patient Management system since its introduction in 2006, making it the most rapidly adopted remote cardiac device monitoring system in the industry. The LATITUDE system allows physicians to schedule remote check-ups of implantable cardiac devices to monitor specific device information and patient heart health status. It can also detect clinical events between scheduled follow-up visits and send relevant data directly to physicians. This regular in-home monitoring offers convenience and peace of mind for patients.
"The ALTITUDE clinical science initiative will enhance physician
understanding of device therapy in real-world practice and offer insights
into event rates and disease progression in the ICD and CRT-D patient
populations," said Leslie Saxon, M.D., F.A.C.C., Chief, Cardiovascular
Medicine in the Cardiovascular and Thoracic Institute, University of
Southern California, and chairperson of the ALTITUDE physician
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved